Abstract
Background
Very little is known about the dermal uptake of isocyanates, and dermal exposure to isocyanates has been discussed as a factor involved in the induction of respiratory diseases.
Objectives
To investigate the dermal uptake of diphenylmethane-4,4’-diisocyanate (4,4’-MDI).
Materials & Methods
Four volunteers were dermally exposed to 10, 25, 49 and 50 mg 4,4’-MDI, respectively, for eight hours. The exposed areas were tape stripped. Urine and blood were biologically monitored for 48 hours. Tape strips, plasma, and urine were analysed by liquid chromatography-mass spectrometry.
Results
In total, 35-70% of the applied dose of 4,4’-MDI was absorbed by the skin. Very low fractions of applied dose were found in the tape strips. The 4,4’-MDA concentration in plasma and urine was low, but peaked in urine at 10-14 hours and plasma at 8-32 hours after exposure.
Conclusions
4,4’-MDI is readily absorbed by human skin. Only small fractions of 4,4’-MDI remain as such in the superficial skin layers. The amounts found in blood and urine were only small fractions of the total applied doses which indicates that very small amounts of 4,4’-MDI penetrate the skin and reach the blood stream. The dermal uptake and distribution of 4,4’-MDI is much slower compared to that associated with airway uptake. Our data strongly indicate that formation of 4,4’-MDA from 4,4’-MDI upon reacting with water in the skin can only occur to a very limited extent.
Similar content being viewed by others
References
McDonald JC, Chen Y, Zekveld C, Cherry NM. Incidence by occupation and industry of acute work related respiratory diseases in the UK, 1992-2001. Occup Environ Med 2005; 62: 836–42.
Redlich CA. Skin exposure and asthma: is there a connection? Proc Am Thorac Soc 2010; 7: 134–7.
Redlich CA, Herrick CA. Lung/skin connections in occupational lung disease. Curr Opin Allergy Clin Immunol 2008; 8: 115–9.
Rattray NJ, Botham PA, Hext PM, et al. Induction of respiratory hypersensitivity to diphenylmethane-4,4’-diisocyanate (MDI) in guinea pigs. Influence of route of exposure. Toxicology 1994; 88: 15–30.
Engfeldt M, Isaksson M, Zimerson E, Bruze M. Several cases of work-related allergic contact dermatitis caused by isocyanates at a company manufacturing heat exchangers. Contact Dermatitis 2013; 68: 175–80.
Agency SC. The Swedish Chemicals Agency’s Classification and labelling regulations (KIFS 7). Stockholm, 2005.
Engfeldt M, Goossens A, Isaksson M, Zimerson E, Bruze M. The outcome of 9 years of consecutive patch testing with 4,4’-diaminodiphenylmethane and 4,4’-diphenylmethane diisocyanate. Contact Dermatitis 2013; 68: 98–102.
Hoffmann HD, Leibold E, Ehnes C, et al. Dermal uptake and excretion of 14C-toluene diisocyante (TDI) and 14C-methylene diphenyl diisocyanate (MDI) in male rats. Clinical signs and histopathology following dermal exposure of male rats to TDI. Toxicol Let 2010; 199: 364–71.
Vock EH, Lutz WK. Distribution and DNA adduct formation of radiolabeled methylenediphenyl-4,4’-diisocyanate (MDI) in the rat after topical treatment. Toxicol Let 1997; 92: 93–100.
Bello D, Smith TJ, Woskie SR, et al. An FTIR investigation of isocyanate skin absorption using in vitro guinea pig skin. J Environ Monit 2006; 8: 523–9.
Hamada H, Isaksson M, Bruze M, et al. Dermal uptake study with 4,4’-diphenylmethane diisocyanate led to active sensitization. Contact Dermatitis 2012; 66: 101–5.
Fent KW, Jayaraj K, Gold A, Ball LM, Nylander-French LA. Tapestrip sampling for measuring dermal exposure to 1,6-hexamethylene diisocyanate. Scand J Work Environ Health 2006; 32: 225–40.
Sennbro CJ, Lindh CH, Tinnerberg H, et al. Development, validation and characterization of an analytical method for the quantification of hydrolysable urinary metabolites and plasma protein adducts of 2,4-and 2,6-toluene diisocyanate, 1,5-naphthalene diisocyanate and 4,4’-methylenediphenyl diisocyanate. Biomarkers 2003; 8: 204–17.
Robert A, Ducos P, Francin JM, Marsan P. Biological monitoring of workers exposed to 4,4’-methylenediphenyl diisocyanate (MDI) in 19 French polyurethane industries. Int Arch Occup Environ Health 2007; 80: 412–22.
Vock EH, Hoymann HG, Heinrich U, Lutz WK. 32P-postlabeling of a DNA adduct derived from 4,4’-methylenedianiline, in the olfactory epithelium of rats exposed by inhalation to 4,4’-methylenediphenyl diisocyanate. Carcinogenesis 1996; 17: 1069–73.
Sepai O, Henschler D, Sabbioni G. Albumin adducts, hemoglobin adducts and urinary metabolites in workers exposed to 4,4’-methylenediphenyl diisocyanate. Carcinogenesis 1995; 16: 2583–7.
Schutze D, Sepai O, Lewalter J, Miksche L, Henschler D, Sabbioni G. Biomonitoring of workers exposed to 4,4’-methylenedianiline or 4,4’-methylenediphenyl diisocyanate. Carcinogenesis 1995; 16: 573–82.
Kim HO, Wester RC, McMaster JA, Bucks DA, Maibach HI. Skin absorption from patch test systems. Contact Dermatitis 1987; 17: 178–80.
Pauluhn J, Lewalter J. Analysis of markers of exposure to polymeric methylene-diphenyl diisocyanate (pMDI) in rats: a comparison of dermal and inhalation routes of exposure. Exp Toxicol Pathol 2002; 54: 135–46.
Sennbro CJ, Lindh CH, Mattsson C, Jonsson BA, Tinnerberg H. Biological monitoring of exposure to 1,5-naphthalene diisocyanate and 4,4’-methylenediphenyl diisocyanate. Int Arch Occup Environ Health 2006; 79: 647–53.
Kaaria K, Hirvonen A, Norppa H, Piirila P, Vainio H, Rosenberg C. Exposure to 4,4’-methylenediphenyl diisocyanate (MDI) during moulding of rigid polyurethane foam: determination of airborne MDI and urinary 4,4’-methylenedianiline (MDA). Analyst 2001; 126: 476–9.
Pearson RL, Logan PW, Kore AM, Strom CM, Brosseau LM, Kingston RL. Isocyanate exposure assessment combining industrial hygiene methods with biomonitoring for end users of orthopedic casting products. Ann Occup Hyg 2013; 57: 758–65.
Hotchkiss SA, Hewitt P, Caldwell J. Percutaneous absorption of 4,4’-methylene-bis (2-chloroaniline) and 4,4’-methylenedianiline through rat and human skin in vitro. Toxicol In Vitro 1993; 7: 141–8.
Brunmark P, Bruze M, Skerfving S, Skarping G. Biomonitoring of 4,4’ methylene dianiline by measurement in hydrolysed urine and plasma after epicutaneous exposure in humans. Int Arch Occup Environ Health 1995; 67: 95–100.
Frick-Engfeldt M, Isaksson M, Zimerson E, Bruze M. How to optimize patch testing with diphenylmethane diisocyanate. Contact Dermatitis 2007; 57: 138–51.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Hamada, H., Liljelind, I., Bruze, M. et al. Assessment of dermal uptake of diphenylmethane-4,4’-diisocyanate using tape stripping and biological monitoring. Eur J Dermatol 28, 143–148 (2018). https://doi.org/10.1684/ejd.2018.3247
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2018.3247